Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.58 |
| ▸ | NPY4R | P50391 | 3/20 | 0.54 |
| ▸ | NPY1R | P25929 | 2/20 | 0.54 |
| ▸ | NPY2R | P49146 | 2/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.53 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24360693 | 0.98 | OPRK1 (0.66) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL30689267 | 0.97 | OPRK1 (0.59) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL18176633 | 0.95 | OPRK1 (0.65) | OPRK1OPRM1NMUR2NMUR1 | |
| SCHEMBL31384592 | 0.95 | NPY4R (0.60) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL31384595 | 0.95 | NPY4R (0.60) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL30689268 | 0.95 | OPRK1 (0.58) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL29972993 | 0.92 | NMUR2 (0.60) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL11930368 | 0.92 | OPRK1 (0.53) | OPRK1OPRM1NMUR2NMUR1 | |
| SCHEMBL30634738 | 0.91 | NMUR2 (0.56) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL18176632 | 0.91 | OPRK1 (0.60) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | OPRK1 1/4885OPRM1 4/4885NPY4R 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.